California’s Medicaid program is making it easier for people with diabetes to obtain the supplies and equipment they need to manage their blood sugar, partly by relaxing preauthorization requirements that can cause life-threatening delays.
Category: drug costs
An Arm and a Leg: John Green vs. Johnson & Johnson (Part 2)
The high price of lifesaving tuberculosis drugs makes them inaccessible to many who need them most. On this episode of “An Arm and a Leg,” hear how a decades-long global fight to reform drug patents is helping to lower the cost.
A New Era of Vaccines Leaves Old Questions About Prices Unanswered
The CDC’s RSV vaccination recommendations beg the question: How much should an immunization that will possibly be given to millions of Americans cost to be truly valuable?
Biden Pick to Lead NIH Finally Has Her Day, but Still Gets Caught Up in Drug Price Debate
Monica Bertagnolli, the president’s choice to head the National Institutes of Health, appeared before a Senate committee this week. Her confirmation has been held up by Sen. Bernie Sanders (I-Vt.), who has demanded President Joe Biden work more aggressively to lower prescription drug prices.
KFF Health News’ ‘What the Health?’: Health Funding in Question in a Speaker-Less Congress
A bitterly divided Congress managed to keep the federal government running for several more weeks, while House Republicans struggle — again — to choose a leader. Meanwhile, many people removed from state Medicaid rolls are not finding their way to Affordable Care Act insurance, and a major investigation by The Washington Post attributes the decline in U.S. life expectancy to more than covid-19 and opioids. Lauren Weber of The Washington Post, Victoria Knight of Axios, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews physician-author-playwright Samuel Shem about “Our Hospital,” his new novel about the health workforce in the age of covid.
An Arm and a Leg: John Green vs. Johnson & Johnson (Part 1)
Pharmaceutical patents can drive up the costs of lifesaving medications. Hear what author and YouTube star John Green is doing to make tuberculosis drugs more accessible to the people who need them most.
KFF Health News’ ‘What the Health?’: Countdown to Shutdown
Congress appears to be careening toward a government shutdown, as a small band of House conservatives vow to block any funding for the fiscal year that begins Oct. 1 unless they win deeper cuts to health and other domestic programs. Meanwhile, former President Donald Trump continues to roil the GOP presidential primary field, this time with comments about abortion. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Tami Luhby of CNN join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
KFF Health News’ ‘What the Health?’: Welcome Back, Congress. Now Get to Work.
Congress returns from its summer recess with a long list of tasks and only a few work days to get them done. On top of the annual spending bills needed to keep the government operating, on the list are bills to renew the global HIV/AIDS program, PEPFAR, and the community health centers program. Meanwhile, over the recess, the Biden administration released the names of the first 10 drugs selected for the Medicare price negotiation program.
5 Things to Know About the New Drug Pricing Negotiations
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
